ArticleFrontiers in cardiovascular medicine2025
Body mass index impacts the lipid-lowing effects of statins in patients with type 2 diabetes.
Article in Frontiers in cardiovascular medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Individuals diagnosed with type 2 diabetes mellitus (T2DM) commonly exhibit elevated lipid levels and an increased body mass index (BMI). The impact of BMI on the efficacy of statins in reducing lipid levels among diabetic patients remains uncertain. We aim to evaluate whether BMI will affect the lipid-lowing effects of statins in patients with T2DM. Methods: In this retrospective analysis, we screened T2DM patients who were prescribed statins and underwent a 1-year outpatient follow-up recorded in the electronic medical record system. Patients were stratified into three groups: normal weight (BMI < 24 kg/m), overweight (24 kg/m Results: This study included 289 patients, with 82 in normal weigh, 143 in overweight, and 64 in obese. Overweight and obese patients were found to be younger than those with normal weight. Over the 1-year follow-up period, lipid levels decreased in all patients, with a significant reduction observed in LDL-C levels. Notably, obese patients experienced the highest reduction in LDL-C levels compared to the normal and overweight groups (normal weight group Conclusions: The effectiveness of statins in lowering lipid levels appears to be influenced by the patient's BMI in patients with T2DM. T2DM patients with high BMI may derive greater benefits, particularly in LDL reduction, from statin therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.